PMID- 15210402
OWN - NLM
STAT- MEDLINE
DCOM- 20040729
LR  - 20131121
IS  - 0949-2321 (Print)
IS  - 0949-2321 (Linking)
VI  - 9
IP  - 4
DP  - 2004 Apr 30
TI  - Dalteparin: pharmacological properties and clinical efficacy in the prophylaxis 
      and treatment of thromboembolic diseases.
PG  - 215-24
AB  - Dalteparin is a low molecular weight heparin (LMWH) with a mean molecular weight 
      of approximately 5,000. As with the other low molecular weight heparins, 
      dalteparin has certain advantages over unfractionated heparin (UFH) most 
      important of which are improved bio-availability by subcutaneous injection, a 
      prolonged antithrombotic activity which is highly correlated with body weight 
      permitting the once daily administration of the drug. Other possible advantages 
      of LMWH including dalteparin include a lower incidence of heparin induced 
      thrombocytopenia and thrombosis and decreased tendency to produce osteopenia on 
      prolonged administration. Dalteparin has been subjected to a large number of well 
      designed randomised clinical trials for the prevention and treatment of venous 
      thromboembolism. Based on data from the randomised clinical trials, dalteparin 
      has been approved internationally for a wide spectrum of clinical indications.
FAU - Pineo, Graham F
AU  - Pineo GF
AD  - University of Calgary, Thrombosis Research Unit, Foothills Hospital, Calgary, AB, 
      Canada.
FAU - Hull, Russell D
AU  - Hull RD
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Eur J Med Res
JT  - European journal of medical research
JID - 9517857
RN  - 0 (Anticoagulants)
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - S79O08V79F (Dalteparin)
SB  - IM
MH  - Anticoagulants/*therapeutic use
MH  - Blood Coagulation/drug effects
MH  - Coronary Disease/complications
MH  - Dalteparin/pharmacokinetics/*pharmacology/*therapeutic use
MH  - Heparin, Low-Molecular-Weight/therapeutic use
MH  - Humans
MH  - Molecular Weight
MH  - Neoplasms/drug therapy/surgery
MH  - Surgical Procedures, Operative
MH  - Thromboembolism/drug therapy/*prevention & control
RF  - 80
EDAT- 2004/06/24 05:00
MHDA- 2004/07/30 05:00
CRDT- 2004/06/24 05:00
PHST- 2004/06/24 05:00 [pubmed]
PHST- 2004/07/30 05:00 [medline]
PHST- 2004/06/24 05:00 [entrez]
PST - ppublish
SO  - Eur J Med Res. 2004 Apr 30;9(4):215-24.